Suppr超能文献

病理性骨折与骨肉瘤患者的生存结局较差相关吗?一项系统评价和荟萃分析。

Are Pathologic Fractures in Patients With Osteosarcoma Associated With Worse Survival Outcomes? A Systematic Review and Meta-analysis.

机构信息

Division of Orthopaedic Oncology, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Department of Orthopaedic Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

出版信息

Clin Orthop Relat Res. 2023 Dec 1;481(12):2433-2443. doi: 10.1097/CORR.0000000000002687. Epub 2023 May 12.

Abstract

BACKGROUND

Pathologic fractures occur in 5% to 10% of patients with osteosarcoma, and prior studies have suggested they are prognostically important. However, because they represent an uncommon event in the setting of an already rare disease, most studies fail to reach conclusive findings, and there is no agreement about how best to treat pathologic fractures.

QUESTIONS/PURPOSES: (1) Is the occurrence of a pathologic fracture in patients with osteosarcoma associated with poorer overall survivorship? (2) Is the occurrence of a pathologic fracture in patients with osteosarcoma associated with poorer local recurrence-free survival or metastasis-free survival? (3) Is the surgical approach (amputation or limb salvage) associated with differences in local recurrence rates in patients with osteosarcoma with pathologic fractures?

METHODS

This systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Our study was registered in PROSPERO (ID: 380459). A search of the PubMed and Embase databases resulted in 625 and 747 titles, respectively. After application of the inclusion and exclusion criteria, 21 articles were finally included. Quality assessment of all studies was performed using the Newcastle-Ottawa Quality Assessment Scale. The Risk of Bias In Non-Randomized Studies of Interventions tool was used in the 11 articles that evaluated the effect of an intervention (amputation or limb salvage) on local recurrence rates. The relative risk (RR) was calculated to compare outcomes in patients with osteosarcoma with pathologic fractures and those without. Heterogeneity among studies was calculated using the I 2 statistic. The pooled RR was calculated using the fixed-effects or random-effects model depending on study heterogeneity. The fragility index and the ratio between the fragility index and the total number of participants for each outcome was additionally calculated to assess the robustness of our results. A total of 7604 patients with osteosarcoma, 12% of whom (885) had pathologic fractures, were included in our analysis.

RESULTS

Pathologic fractures in patients with osteosarcoma were associated with lower 3-year (RR 1.53 [95% CI 1.29 to 1.82]; p < 0.001) and 5-year overall survival (RR 1.27 [95% CI 1.16 to 1.40]; p < 0.001). No difference in recurrence rates was found between patients with osteosarcoma with pathologic fractures and those without (RR 1.22 [95% CI 0.91 to 1.64]; p = 0.18). However, having a pathologic fracture was associated with an increased risk of developing metastasis (RR 1.33 [95% CI 1.08 to 1.63]; p = 0.01). Treatment with limb salvage surgery was not associated with a higher rate of local recurrence (RR 1.58 [95% CI 0.88 to 2.85]; p = 0.13).

CONCLUSION

In light of these findings, surgeons should be aware that after appropriate case selection, patients with osteosarcoma and pathologic fractures undergoing limb salvage surgery may have similar rates of local recurrence to those undergoing amputation. Therefore, a pathologic fracture may no longer be an absolute contraindication for limb salvage surgery. Future studies adjusting for potential confounders such as tumor size, tumor location, and response to neoadjuvant therapy would provide further insight into the effect of pathologic fractures on our assessed outcomes.

LEVEL OF EVIDENCE

Level III, therapeutic study.

摘要

背景

病理性骨折发生在 5%-10%的骨肉瘤患者中,既往研究表明其具有预后意义。然而,由于在已经罕见的疾病中,病理性骨折是一种罕见的事件,大多数研究无法得出明确的结论,并且对于如何最好地治疗病理性骨折也没有共识。

问题/目的:(1)骨肉瘤患者发生病理性骨折是否与总体生存率降低有关?(2)骨肉瘤患者发生病理性骨折是否与局部无复发生存率或无转移生存率降低有关?(3)在患有病理性骨折的骨肉瘤患者中,手术方式(截肢或保肢)是否与局部复发率的差异有关?

方法

本系统评价遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南进行。我们的研究在 PROSPERO(ID:380459)中进行了注册。对 PubMed 和 Embase 数据库的搜索分别产生了 625 个和 747 个标题。在应用纳入和排除标准后,最终纳入了 21 篇文章。使用纽卡斯尔-渥太华质量评估量表(Newcastle-Ottawa Quality Assessment Scale)对所有研究进行质量评估。在评估干预措施(截肢或保肢)对局部复发率影响的 11 篇文章中,使用了干预措施的非随机研究风险偏倚工具(Risk of Bias In Non-Randomized Studies of Interventions)。计算相对风险(RR)以比较患有和不患有骨肉瘤病理性骨折患者的结局。使用 I 2 统计量计算研究之间的异质性。根据研究异质性,使用固定效应或随机效应模型计算汇总 RR。此外,还计算了每个结局的脆弱性指数和脆弱性指数与参与者总数之间的比值,以评估我们结果的稳健性。共有 7604 名患有骨肉瘤的患者被纳入我们的分析,其中 12%(885 名)发生了病理性骨折。

结果

骨肉瘤患者发生病理性骨折与 3 年(RR 1.53 [95%CI 1.29 至 1.82];p < 0.001)和 5 年总体生存率(RR 1.27 [95%CI 1.16 至 1.40];p < 0.001)降低有关。患有病理性骨折的骨肉瘤患者与未发生病理性骨折的患者之间的复发率没有差异(RR 1.22 [95%CI 0.91 至 1.64];p = 0.18)。然而,发生病理性骨折与发生转移的风险增加有关(RR 1.33 [95%CI 1.08 至 1.63];p = 0.01)。保肢手术治疗与局部复发率较高无关(RR 1.58 [95%CI 0.88 至 2.85];p = 0.13)。

结论

鉴于这些发现,外科医生应该意识到,在适当的病例选择后,接受保肢手术治疗的骨肉瘤合并病理性骨折患者与接受截肢手术的患者的局部复发率可能相似。因此,病理性骨折可能不再是保肢手术的绝对禁忌证。未来的研究应调整肿瘤大小、肿瘤位置和新辅助治疗反应等潜在混杂因素,进一步深入了解病理性骨折对我们评估结果的影响。

证据水平

III 级,治疗性研究。

相似文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验